Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 3Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia, Myeloid, Chronic-Phase 4Burkitt Lymphoma 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Lymphoma 2Leukemia 2Hematologic Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Substance Withdrawal Syndrome 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Ovarian Neoplasms 1Neoplasms 1Neoplasm, Residual 1Multiple Myeloma 1Melanoma 1Lung Neoplasms 1Leukemia, Biphenotypic, Acute 1Glioma 1Frailty 1Esophageal Neoplasms 1Endometrial Neoplasms 1

Interventions

nilotinib 2asciminib 2bosutinib 1Imatinib Mesylate 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Philadelphia Chromosome × Dasatinib × Clear all
NCT04971226 2026-06-05

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡